Eli Lilly logo is shown on one of the company's ... The new investment, which will bring the company's cumulative investment in China to exceed 20 billion yuan ($2.81 billion), aims to boost ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...

opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the second to set up shop outside of the U.S. following a ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Eli Lilly (NYSE:LLY) received approval from the ... The drug is potentially the first of its kind to become available in the China region. Lilly’s (LLY) shot has already been approved in ...

In my most recent article about Eli Lilly and Company, I reaffirmed the company as a 'hold' candidate. This was in spite of the fact that the business had achieved a big win in China and that ...

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...

Yet, Eli Lilly's GLP-1 medications are helping it compete ... A few months later, Wegovy was approved to enter yet another market: China, a geographic region where obesity rates are quite high.

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.